Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Down 18.8% in April

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a significant decrease in short interest in April. As of April 15th, there was short interest totaling 30,580 shares, a decrease of 18.8% from the March 31st total of 37,653 shares. Based on an average daily trading volume, of 21,081 shares, the short-interest ratio is presently 1.5 days. Currently, 0.6% of the shares of the company are sold short.

Institutional Investors Weigh In On Evaxion A/S

Hedge funds have recently modified their holdings of the business. SmartHarvest Portfolios LLC acquired a new stake in shares of Evaxion A/S in the fourth quarter valued at about $72,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Evaxion A/S in the fourth quarter valued at about $38,000. Finally, Wesbanco Bank Inc. acquired a new stake in shares of Evaxion A/S in the fourth quarter valued at about $48,000. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion A/S Price Performance

EVAX traded up $0.08 during midday trading on Friday, hitting $4.49. 30,048 shares of the company traded hands, compared to its average volume of 31,768. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $37.45 million, a price-to-earnings ratio of -3.40 and a beta of 0.26. Evaxion A/S has a 52-week low of $1.42 and a 52-week high of $12.15. The business has a 50 day simple moving average of $3.82 and a two-hundred day simple moving average of $4.70.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Maxim Group assumed coverage on shares of Evaxion A/S in a report on Thursday, February 19th. They set a “buy” rating and a $10.00 price target on the stock. JonesTrading assumed coverage on shares of Evaxion A/S in a report on Tuesday, March 10th. They set a “buy” rating and a $10.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Lake Street Capital decreased their price objective on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Finally, Wall Street Zen downgraded shares of Evaxion A/S from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.